. Ifosfamide-vidal, fr [Internet]. [cité 14 févr 2016]. Disponible sur: https

S. Yule, L. Price, A. Pearson, and A. Boddy, Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children, Clin Cancer Res Off J Am Assoc Cancer Res. nov, vol.3, issue.11, pp.1985-92, 1997.

G. Kaijser, D. Kraker, J. Bult, A. Underberg, W. Beijnen et al., Pharmacokinetics of ifosfamide and some metabolites in children, Anticancer Res. juin, vol.18, issue.3B, pp.1941-1950, 1998.

R. Struck, D. Dykes, T. Corbett, W. Suling, and M. Trader, Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide, British Journal of Cancer, vol.47, issue.1, pp.15-26, 1983.
DOI : 10.1038/bjc.1983.2

K. Cauwenberghe, Activated oxazaphosphorines are transported predominantly by erythrocytes, Ann Oncol Off J Eur Soc Med Oncol ESMO. nov, vol.8, issue.11, pp.1139-1183, 1997.

M. Highley, G. Momerency, D. Sawyers, E. Bruijn, H. Prenen et al., The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide, Journal of Analytical Oncology, vol.4, issue.1, pp.13-23, 2015.
DOI : 10.6000/1927-7229.2015.04.01.3

L. Allen and P. Creaven, Pharmacokinetics of ifosfamide, Clinical Pharmacology & Therapeutics, vol.17, issue.4, pp.492-500, 1975.
DOI : 10.1002/cpt1975174492

T. Kerbusch, J. De-kraker, H. Keizer, J. Van-putten, H. Groen et al., Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites, Clinical Pharmacokinetics, vol.11, issue.11, pp.41-62, 2001.
DOI : 10.2165/00003088-200140010-00004

R. Preiss, R. Schmidt, F. Baumann, H. Hanschmann, J. Hauss et al., Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide, Journal of Cancer Research and Clinical Oncology, vol.128, issue.7, pp.385-92, 2002.
DOI : 10.1007/s00432-002-0335-4

P. Dockham, L. Sreerama, and N. Sladek, Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines, Drug Metab Dispos Biol Fate Chem. déc, vol.25, issue.12, pp.1436-1477, 1997.

P. Schwartz, C. Chen, and D. Waxman, Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy, Cancer Gene Therapy, vol.10, issue.8, pp.571-82, 2003.
DOI : 10.1038/sj.cgt.7700601

M. Lind, J. Margison, T. Cerny, N. Thatcher, and P. Wilkinson, Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma, Cancer Res, vol.49, issue.3, pp.753-760, 1989.

A. Boddy and Y. Sm, Metabolism and Pharmacokinetics of Oxazaphosphorines, Clinical Pharmacokinetics, vol.5, issue.4, pp.291-304, 2000.
DOI : 10.2165/00003088-200038040-00001

T. Kerbusch, R. Mathôt, H. Keizer, G. Kaijser, J. Schellens et al., Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites, Drug Metab Dispos Biol Fate Chem. juill, vol.29, issue.7, pp.967-75, 2001.

A. Boddy, M. Cole, A. Pearson, and J. Idle, The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion, Cancer Chemotherapy and Pharmacology, vol.45, issue.1, pp.53-60, 1995.
DOI : 10.1007/BF00685732

G. Fasola, L. Greco, P. Calori, E. Zilli, M. Verlicchi et al., Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation, Haematologica. avr, vol.76, issue.2, pp.120-125, 1991.

N. Brock and J. Pohl, Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics, IARC Sci Publ, issue.78, pp.269-79, 1986.

J. Klastersky, Side Effects of Ifosfamide, Oncology, vol.65, issue.2, pp.7-10, 2003.
DOI : 10.1159/000073351

P. Nicolao and B. Giometto, Neurological Toxicity of Ifosfamide, Oncology, vol.65, issue.2, pp.11-17, 2003.
DOI : 10.1159/000073352

A. Szabatura, F. Cirrone, C. Harris, A. Mcdonnell, Y. Feng et al., An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center, Journal of Oncology Pharmacy Practice, vol.38, issue.3, pp.188-93, 2015.
DOI : 10.1177/1078155214527143

J. Van-dyk and H. , Unexpected toxicity in patients treated with Iphosphamide, Cancer Res, vol.32, issue.5, pp.921-925, 1972.

F. Lokiec, Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention, Annals of Oncology, vol.17, issue.suppl 4, pp.33-39, 2006.
DOI : 10.1093/annonc/mdj997

M. Goren, R. Wright, C. Pratt, and F. Pell, DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY, The Lancet, vol.328, issue.8517, pp.1219-1239, 1986.
DOI : 10.1016/S0140-6736(86)92227-0

R. Nelson, P. Creaven, M. Cohen, and B. Fossieck, Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724), European Journal of Cancer (1965), vol.12, issue.3, pp.195-203, 1976.
DOI : 10.1016/0014-2964(76)90241-3

R. Issels, T. Meier, E. Müller, G. Multhoff, and W. Wilmanns, Ifosfamide induced stress response in human lymphocytes, Molecular Aspects of Medicine, vol.14, issue.3, pp.281-287, 1993.
DOI : 10.1016/0098-2997(93)90016-7

C. Sood, O. Brien, and P. , Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes, Biochemical Pharmacology, vol.46, issue.9, pp.1621-1627, 1993.
DOI : 10.1016/0006-2952(93)90332-Q

C. Sood, O. Brien, and P. , Chloroacetaldehyde-induced hepatocyte cytotoxicity, Biochemical Pharmacology, vol.48, issue.5, pp.1025-1057, 1994.
DOI : 10.1016/0006-2952(94)90374-3

T. Visarius, J. Stucki, and B. Lauterburg, Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats, J Pharmacol Exp Ther. mai, vol.289, issue.2, pp.820-824, 1999.

U. Hofmann, M. Eichelbaum, S. Seefried, and C. Meese, Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine, Drug Metab Dispos Biol Fate Chem. févr, vol.19, issue.1, pp.222-228, 1991.

T. Visarius, H. Bähler, A. Küpfer, T. Cerny, and B. Lauterburg, Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats, Drug Metab Dispos Biol Fate Chem. mars, vol.26, issue.3, pp.193-199, 1998.

R. Peters, Croonian Lecture: Lethal Synthesis, Proceedings of the Royal Society B: Biological Sciences, vol.139, issue.895, pp.143-70, 1952.
DOI : 10.1098/rspb.1952.0001

J. Chatton, J. Idle, C. Vågbø, and P. Magistretti, Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons, J Pharmacol Exp Ther. déc, vol.299, issue.3, pp.1161-1169, 2001.

G. Kaijser, H. Keizer, J. Beijnen, A. Bult, and W. Underberg, Pharmacokinetics of ifosfamide, 2-and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide, Anticancer Res. oct, vol.16, issue.5B, pp.3247-57, 1996.

A. Küpfer, C. Aeschlimann, B. Wermuth, and T. Cerny, Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue, The Lancet, vol.343, issue.8900, pp.763-767, 1994.
DOI : 10.1016/S0140-6736(94)91839-2

T. Cerny and A. Küpfer, Editorial: The enigma of ifosfamide encephalopathy, Annals of Oncology, vol.3, issue.9, pp.679-81, 1992.
DOI : 10.1093/oxfordjournals.annonc.a058317

T. Wagner, Ifosfamide Clinical Pharmacokinetics, Clinical Pharmacokinetics, vol.26, issue.6, pp.439-56, 1994.
DOI : 10.2165/00003088-199426060-00003

H. Ho-null and C. Yuen, Aprepitant-associated ifosfamide neurotoxicity, J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. juin, vol.16, issue.2, pp.137-145, 2010.

J. Howell, A. Szabatura, H. Seung, A. Nesbit, and S. , Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, Journal of Oncology Pharmacy Practice, vol.23039, issue.3, pp.157-62, 2008.
DOI : 10.1177/1078155208093930

M. Williams and I. Wainer, Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question, Curr Pharm Des. août, vol.5, issue.8, pp.665-72, 1999.

C. Aeschlimann, A. Küpfer, H. Schefer, and T. Cerny, Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy, Drug Metab Dispos Biol Fate Chem. sept, vol.26, issue.9, pp.883-90, 1998.

K. Sweiss, R. Beri, and S. Shord, Encephalopathy after High-Dose Ifosfamide, Drug Safety, vol.121, issue.39, pp.989-96, 2008.
DOI : 10.2165/00002018-200831110-00003

J. Durand, B. Gourmel, O. Mir, and F. Goldwasser, Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy, Annals of Oncology, vol.18, issue.4, pp.808-817, 2007.
DOI : 10.1093/annonc/mdm104

URL : http://annonc.oxfordjournals.org/cgi/content/short/18/4/808

J. Neustadt and S. Pieczenik, Medication???induced mitochondrial damage and disease, Molecular Nutrition & Food Research, vol.46, issue.7, pp.780-788, 2008.
DOI : 10.1002/mnfr.200700075

R. Magge and L. Deangelis, The double-edged sword: Neurotoxicity of chemotherapy, Blood Reviews, vol.29, issue.2
DOI : 10.1016/j.blre.2014.09.012

G. Ginsberg, D. Hattis, and B. Sonawane, Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants, Toxicology and Applied Pharmacology, vol.198, issue.2, pp.164-83, 2004.
DOI : 10.1016/j.taap.2003.10.010